Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.
Objectives:
To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.
Methods:
This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients–Intervention–Comparator–Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.
Results:
A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.
Conclusion:
The present guideline will enable homogeneity of treatment decisions across Europe.
NoseworthyJHLucchinettiCRodriguezM, et al. Multiple sclerosis. N Engl J Med2000; 343(13): 938–952.
2.
KingwellEZhuFMarrieRA, et al. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: Findings from over two decades (1991–2010). J Neurol2015; 262(10): 2352–2363.
3.
GryttenNAarsethJHLundeHM, et al. A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. J Neurol Neurosurg Psychiatry2016; 87(1): 100–105.
4.
BrownePChandraratnaDAngoodC, et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology2014; 83(11): 1022–1024.
5.
KobeltGThompsonABergJ, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler2017; 23: 1123–1136.
6.
StawowczykEMalinowskiKPKawalecP, et al. The indirect costs of multiple sclerosis: Systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res2015; 15(5): 759–786.
7.
ConfavreuxCVukusicS.Natural history of multiple sclerosis: A unifying concept. Brain2006; 129(Pt 3): 606–616.
8.
WeinshenkerBGBassBRiceGP, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain1989; 112(Pt 1): 133–146.
WinkelmannALoebermannMReisingerEC, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol2016; 12(4): 217–233.
13.
SubeiAMOntanedaD.Risk mitigation strategies for adverse reactions associated with the disease-modifying drugs in multiple sclerosis. CNS Drugs2015; 29(9): 759–771.
14.
McDonaldWICompstonAEdanG, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50(1): 121–127.
15.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
16.
PolmanCHReingoldSCEdanG, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol2005; 58(6): 840–846.
17.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. Epub ahead of print December212017. DOI: 10.1016/S1474-4422(17)30470-2.
18.
LublinFDReingoldSCCohenJA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2014; 83(3): 278–286.
19.
TintoreMRoviraARioJ, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015; 138(Pt 7): 1863–1874.
20.
JokubaitisVGSpelmanTKalincikT, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol2016; 80(1): 89–100.
21.
DegenhardtARamagopalanSVScalfariA, et al. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol2009; 5(12): 672–682.
22.
BroadleySABarnettMHBoggildM, et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. J Clin Neurosci2014; 21(11): 1847–1856.
23.
CorrealeJAbadPAlvarengaR, et al. Management of relapsing-remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization. J Neurol Sci2014; 339(1–2): 196–206.
24.
National Clinical Guideline. National Institute for Health and Care Excellence: Clinical Guidelines. Multiple Sclerosis: Management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Care Excellence, 2014.
25.
YamoutBAlroughaniRAl-JumahM, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: The Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin2015; 31(7): 1349–1361.
26.
LublinFDReingoldSC.Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46(4): 907–911.
27.
ChitnisTTenembaumSBanwellB, et al. Consensus statement: Evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler2012; 18(1): 116–127.
28.
WassmerEChitnisTPohlD, et al. International pediatric MS study group global members symposium report. Neurology2016; 87(9Suppl. 2): S110–S116.
29.
KruppLBTardieuMAmatoMP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler2013; 19(10): 1261–1267.
30.
TardieuMBanwellBWolinskyJS, et al. Consensus definitions for pediatric MS and other demyelinating disorders in childhood. Neurology2016; 87(9Suppl. 2): S8–S11.
31.
GuyattGOxmanADAklEA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol2011; 64(4): 383–394.
32.
LeoneMAKeindlMSchapiraAH, et al. Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces. Eur J Neurol2015; 22(12): 1505–1510.
33.
HigginsJPTGreenS.Cochrane Handbook for Systematic Review of Interventions. The Cochrane Collaboration, 2008
34.
SterneJAHernanMAReevesBC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016; 355: i4919.
35.
GuyattGHOxmanADVistGE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008; 336(7650): 924–926.
36.
RankinNMMcGregorDButowPN, et al. Adapting the nominal group technique for priority setting of evidence-practice gaps in implementation science. BMC Med Res Methodol2016; 16(1): 110.
37.
MurphyMKBlackNALampingDL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess1998; 2(3): i–iv, 1–88.
38.
ComiGDe StefanoNFreedmanMS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial. Lancet Neurol2012; 11(1): 33–41.
39.
ComiGMartinelliVRodegherM, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet2009; 374(9700): 1503–1511.
40.
JacobsLDBeckRWSimonJH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med2000; 343(13): 898–904.
41.
KapposLPolmanCHFreedmanMS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006; 67(7): 1242–1249.
42.
MillerAEWolinskyJSKapposL, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13(10): 977–986.
43.
ComiGMartinelliVRodegherM, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler2013; 19(8): 1074–1083.
44.
KapposLEdanGFreedmanMS, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology2016; 87(10): 978–987.
45.
KinkelRPKollmanCO’ConnorP, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology2006; 66(5): 678–684.
46.
EdanGKapposLMontalbanX, et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry2014; 85(11): 1183–1189.
47.
KapposLFreedmanMSPolmanCH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet2007; 370(9585): 389–397.
48.
KapposLFreedmanMSPolmanCH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol2009; 8(11): 987–997.
49.
CalabresiPAKieseierBCArnoldDL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol2014; 13(7): 657–665.
50.
VollmerTLSorensenSPSelmajK, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol2014; 261(4): 773–783.
51.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993; 43(4): 655–661.
52.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet1998; 352(9139): 1498–1504.
53.
JacobsLDCookfairDLRudickRA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol1996; 39(3): 285–294.
54.
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology2001; 56(12): 1628–1636.
55.
KieseierBCArnoldDLBalcerLJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler2015; 21(8): 1025–1035.
56.
KapposLTraboulseeAConstantinescuC, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology2006; 67(6): 944–953.
57.
EbersGCTraboulseeALiD, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry2010; 81(8):907–912.
58.
FoxRJMillerDHPhillipsJT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367(12): 1087–1097.
59.
JohnsonKPBrooksBRCohenJA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology1995; 45(7): 1268–1276.
60.
KhanORieckmannPBoykoA, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol2013; 73(6): 705–713.
61.
JohnsonKPBrooksBRFordCC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler2000; 6(4): 255–266.
62.
ConfavreuxCO’ConnorPComiG, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13(3): 247–256.
63.
O’ConnorPWolinskyJSConfavreuxC, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med2011; 365(14): 1293–1303.
64.
O’ConnorPComiGFreedmanMS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology2016; 86(10): 920–930.
65.
GoldRKapposLArnoldDL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367(12): 1098–1107.
66.
GoldRArnoldDLBar-OrA, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE. A randomized extension study. Mult Scler2017; 23: 253–265.
67.
CalabresiPARadueEWGoodinD, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13(6): 545–556.
68.
KapposLRadueEWO’ConnorP, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362(5): 387–401.
69.
KapposLO’ConnorPRadueEW, et al. Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015; 84(15): 1582–1591.
70.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 899–910.
71.
GoldRGiovannoniGSelmajK, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial. Lancet2013; 381(9884): 2167–2175.
72.
GiovannoniGGoldRSelmajK, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): A multicentre, randomised, double-blind extension trial. Lancet Neurol2014; 13(5): 472–481.
73.
GiovannoniGComiGCookS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362(5): 416–426.
74.
CadavidDWolanskyLJSkurnickJ, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009; 72(23): 1976–1983.
75.
CalabreseMBernardiVAtzoriM, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler2012; 18(4): 418–424.
76.
MikolDDBarkhofFChangP, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol2008; 7(10): 903–914.
77.
O’ConnorPFilippiMArnasonB, et al. 250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol2009; 8(10): 889–897.
78.
VermerschPCzlonkowskaAGrimaldiLM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. Mult Scler2014; 20(6): 705–716.
79.
CohenJABarkhofFComiG, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362(5): 402–415.
80.
KhatriBBarkhofFComiG, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study. Lancet Neurol2011; 10(6): 520–529.
81.
CohenJAKhatriBBarkhofF, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry2016; 87(5): 468–475.
82.
KapposLWiendlHSelmajK, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2015; 373(15): 1418–1428.
83.
CohenJAColesAJArnoldDL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1819–1828.
84.
ColesAJCompstonDASelmajKW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med2008; 359(17): 1786–1801.
85.
ColesAJTwymanCLArnoldDL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1829–1839.
86.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
87.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet1998; 352(9139): 1491–1497.
88.
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology2001; 56(11): 1496–1504.
89.
AndersenOElovaaraIFarkkilaM, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry2004; 75(5): 706–710.
90.
PanitchHMillerAPatyD, et al. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology2004; 63(10): 1788–1795.
91.
KuhleJHardmeierMDisantoG, et al. A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis. Mult Scler2016; 22(4): 533–543.
92.
HartungHPGonsetteRKonigN, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet2002; 360(9350): 2018–2025.
93.
LearySMMillerDHStevensonVL, et al. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology2003; 60(1): 44–51.
94.
LublinFMillerDHFreedmanMS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet2016; 387(10023): 1075–1084.
95.
MontalbanX.Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. Mult Scler2004; 10(3 Suppl.): S62–S64.
96.
MontalbanXHauserSLKapposL, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376(3): 209–220.
97.
WolinskyJSNarayanaPAO’ConnorP, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol2007; 61(1): 14–24.
98.
TurCMontalbanXTintoreM, et al. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch Neurol2011; 68(11): 1421–1427.
99.
Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology1999; 53(4): 679–686.
100.
RioJRuiz-PenaJL.Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci2016; 361: 158–167.
101.
SormaniMPGasperiniCRomeoM, et al. Assessing response to interferon-beta in a multicenter dataset of patients with MS. Neurology2016; 87(2): 134–140.
102.
RomeoMMartinelliVRodegherM, et al. Validation of 1-year predictive score of long-term response to interferon-beta in everyday clinical practice multiple sclerosis patients. Eur J Neurol2015; 22(6): 973–980.
103.
HyunJWKimSHJeongIH, et al. Utility of the Rio score and modified Rio score in Korean patients with multiple sclerosis. PLoS ONE2015; 10(5): e0129243.
104.
ProsperiniLMancinelliCRDe GiglioL, et al. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler2014; 20(5): 566–576.
105.
RioJRoviraABlancoY, et al. Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score. Rev Neurol2016; 63(4): 145–150.
106.
RotsteinDLHealyBCMalikMT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol2015; 72(2): 152–158.
107.
ProsperiniLGalloVPetsasN, et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol2009; 16(11): 1202–1209.
108.
SormaniMPRioJTintoreM, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler2013; 19(5): 605–612.
109.
SimonJHLiDTraboulseeA, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol2006; 27(2): 455–461.
110.
CookSDDhib-JalbutSDowlingP, et al. Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course: A report from an international CMSC consensus conference, March 5–7, 2010. Int J MS Care2012; 14(3): 105–114.
111.
WattjesMPRoviraAMillerD, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis–establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11(10): 597–606.
112.
CohenJABarkhofFComiG, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013; 260(8): 2023–2032.
113.
FoxEEdwardsKBurchG, et al. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord2014; 3(5): 607–619.
114.
BergvallNMakinCLahozR, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: A US claims database study. PLoS ONE2014; 9(2): e88472.
115.
BrauneSLangMBergmannA.Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. J Neurol2016; 263(2): 327–333.
116.
HeASpelmanTJokubaitisV, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol2015; 72(4): 405–413.
117.
RioJTintoreMSastre-GarrigaJ, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol2012; 19(6): 899–904.
118.
SpelmanTKalincikTZhangA, et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol2015; 2(4): 373–387.
119.
ProsperiniLGianniCLeonardiL, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler2012; 18(1): 64–71.
120.
Weinstock-GuttmanBHagemeierJKavakKS, et al. Randomised natalizumab discontinuation study: Taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry2016; 87(9): 937–943.
121.
BorrielloGProsperiniLMancinelliC, et al. Pulse monthly steroids during an elective interruption of natalizumab: A post-marketing study. Eur J Neurol2012; 19(5): 783–787.
122.
BorrielloGProsperiniLMarinelliF, et al. Observations during an elective interruption of natalizumab treatment: A post-marketing study. Mult Scler2011; 17(3): 372–375.
123.
ClericoMSchiavettiIDe MercantiSF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: Evidence from an Italian spontaneous, prospective and observational study (the TY-STOP study). JAMA Neurol2014; 71(8): 954–960.
124.
CohenMMaillartETourbahA, et al. Switching from natalizumab to fingolimod in multiple sclerosis: A French prospective study. JAMA Neurol2014; 71(4): 436–441.
125.
EvangelopoulosMEKoutoulidisVAndreadouE, et al. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod. Int J Neurosci2016; 126(12): 1097–1102.
126.
GueguenARouxPDeschampsR, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry2014; 85(9): 1038–1040.
127.
HatcherSEWaubantENourbakhshB, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol2016; 73(7): 790–794.
128.
MagranerMJCoretFNavarreA, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study. J Neurol2011; 258(10): 1805–1811.
129.
MiravalleAJensenRKinkelRP.Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol2011; 68(2): 186–191.
130.
RossiSMottaCStuderV, et al. Treatment options to reduce disease activity after natalizumab: Paradoxical effects of corticosteroids. CNS Neurosci Ther2014; 20(8): 748–753.
131.
SangalliFMoiolaLFerreL, et al. Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Mult Scler Relat Disord2014; 3(4): 520–526.
132.
WestTWCreeBAC. Natalizumab dosage suspension: Are we helping or hurting?Ann Neurol2010; 68(3): 395–399.
133.
HavlaJTackenbergBHellwigK, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol2013; 260(5): 1382–1387.
134.
Lo ReMCapobiancoMRagoneseP, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): A retrospective study from two Italian MS centers. Neurol Ther2015; 4(2): 147–157.
135.
MelisMCoccoEFrauJ, et al. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurol Sci2014; 35(3): 401–408.
136.
RinaldiFSeppiDCalabreseM, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: Clinical and magnetic resonance imaging findings. Mult Scler2012; 18(11): 1640–1643.
137.
Salhofer-PolanyiSBaumgartnerAKrausJ, et al. What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand2014; 130(2): 97–102.
138.
Vidal-JordanaATintoreMTurC, et al. Significant clinical worsening after natalizumab withdrawal: predictive factors. Mult Scler2015; 21(6): 780–785.
139.
AlpingPFrisellTNovakovaL, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol2016; 79(6): 950–958.
140.
IaffaldanoPLucisanoGPozzilliC, et al. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain2015; 138(11): 3275–3286.
141.
FoxRJCreeBACDe SezeJ, et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology2014; 82(17): 1491–1498.
142.
KisterISpelmanTAlroughaniR, et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study. J Neurol Neurosurg Psychiatry2016; 87(10): 1133–1137.
143.
LuEWangBWGuimondC, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology2012; 79(11): 1130–1135.
144.
AmatoMPPortaccioEGhezziA, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology2010; 75(20): 1794–1802.
145.
BoskovicRWideRWolpinJ, et al. The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. Neurology2005; 65(6): 807–811.
146.
CoylePKSinclairSMScheuerleAE, et al. Final results from the Betaseron (interferon beta-1b) Pregnancy Registry: A prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open2014; 4(5): e004536.
147.
De las HerasVDe AndresCTellezN, et al. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: A descriptive study in the Spanish population. Mult Scler2007; 13(8): 981–984.
148.
FaresJNassarAHGebeilyS, et al. Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): A prospective multicentre study. BMJ Open2016; 6(5): e011210.
149.
Fernandez LiguoriNKlajnDAcionL, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult Scler2009; 15(5): 555–562.
150.
FragosoYDBoggildMMacIas-IslasMA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg2013; 115(2): 154–159.
151.
GianniniMPortaccioEGhezziA, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: A prospective observational multicentric study. BMC Neurol2012; 12: 124.
152.
HellwigKHaghikiaARockhoffM, et al. Multiple sclerosis and pregnancy: Experience from a nationwide database in Germany. Ther Adv Neurol Disord2012; 5(5): 247–253.
153.
HerbstrittSLanger-GouldARockhoffM, et al. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler2015; 22(6): 810–816.
154.
LuEDahlgrenLSadovnickAD, et al. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult Scler2012; 18(4): 460–467.
155.
PattiFCavallaroTLo FermoS, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?J Neurol2008; 255(8): 1250–1253.
156.
RomeroRSLunzmannCBuggeJ-P.Pregnancy outcomes in patients exposed to interferon beta-1b. J Neurol Neurosurg Psychiatry2015; 86(5): 587–589.
157.
ShimizuYMakiokaHHaradaN, et al. Outcomes of pregnancy during interferon beta-1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study. Clin Exp Neuroimmunol2015; 6(4): 402–408.
158.
Weber-SchoendorferCSchaeferC.Multiple sclerosis immunomodulators. pregnancy outcome: A prospective observational study. Mult Scler2009; 15(9): 1037–1042.
159.
EbrahimiNHerbstrittSGoldR, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy: A prospective, controlled observational study. Mult Scler2015; 21(2): 198–205.
160.
FriendSRichmanSBloomgrenG, et al. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: A global, observational, follow-up study. BMC Neurol2016; 16(1): 150.
161.
HellwigKHaghikiaAGoldR, et al. Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler2011; 17(8): 958–963.
162.
GoldRPhillipsJTHavrdovaE, et al. Delayed-release dimethyl fumarate and pregnancy: Preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther2015; 4(2): 93–104.
163.
KieseierBCBenamorM.Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther2014; 3(2): 133–138.
164.
KarlssonGFrancisGKorenG, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology2014; 82(8): 674–680.
165.
ThielSLanger-GouldARockhoffM, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis: A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler2015; 22(6): 801–809.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
